Trametinib
- Generic Name
- Trametinib
- Brand Names
- Mekinist, Spexotras
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23FIN5O4
- CAS Number
- 871700-17-3
- Unique Ingredient Identifier
- 33E86K87QN
- Background
Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib is currently approved to treat a variety of c...
- Indication
Trametinib is indicated as monotherapy for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
It is used in combination with dabrafenib for the:
...
- Associated Conditions
- Advanced Non-Small Cell Lung Cancer (NSCLC), Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Stage III Melanoma, Unresectable Melanoma, Unresectable or Metastatic Solid Tumors
- Associated Therapies
- -
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
- Conditions
- Interventions
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 71
- Registration Number
- NCT04111458
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇩🇪Universitätsklinikum Frankfurt, Frankfurt am Main, Germany
🇩🇪Universitätsklinikum Köln (AöR), Köln, Germany
TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Target Recruit Count
- 45
- Registration Number
- NCT04059224
- Locations
- 🇧🇪
Universitair Ziekenhuis Brussel, Jette, Brussels, Belgium
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 6
- Registration Number
- NCT03975231
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Univ of Texas-M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Pediatric Long-Term Follow-up and Rollover Study
- Conditions
- Interventions
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 166
- Registration Number
- NCT03975829
- Locations
- 🇺🇸
Phoenix Children s Hospital, Phoenix, Arizona, United States
🇺🇸Childrens National Hospital, Washington, District of Columbia, United States
🇺🇸Nicklaus Childrens Hospital, Miami, Florida, United States
Pan Tumor Rollover Study
- Conditions
- Interventions
- Drug: NivolumabDrug: LeucovorinDrug: Nivolumab + RelatlimabDrug: RegorafinibDrug: CapecitabineDrug: PemetrexedDrug: EnzalutamideDrug: SunitinibDrug: PembrolizumabDrug: RelatlimabDrug: TemozolomideDrug: RucaparibDrug: IpilimumabDrug: DaratumumabDrug: FluorouracilDrug: CabozantinibDrug: TrametinibDrug: BevacizumabDrug: Oxaliplatin
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1500
- Registration Number
- NCT03899155
- Locations
- 🇧🇷
Local Institution - 0260, Belo Horizonte, Minas Gerais, Brazil
🇨🇳Harbin Medical University - Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Local Institution - 0172, Changsha, Hunan, China
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8AnemiaAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCastration-Resistant Prostate Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AbirateroneDrug: AfatinibBiological: BevacizumabDrug: BicalutamideProcedure: Biospecimen CollectionDrug: BortezomibDrug: CabazitaxelDrug: CabozantinibDrug: CapecitabineDrug: CarboplatinDrug: CelecoxibDrug: CobimetinibDrug: CopanlisibDrug: DabrafenibDrug: DacomitinibDrug: DarolutamideDrug: DasatinibDrug: DoxorubicinBiological: DurvalumabDrug: EnasidenibDrug: EntrectinibDrug: EnzalutamideDrug: ErlotinibDrug: EverolimusDrug: FluorouracilDrug: IdelalisibDrug: ImatinibBiological: IpilimumabDrug: LenvatinibDrug: LeucovorinDrug: LorlatinibDrug: LosartanDrug: Nab-paclitaxelDrug: NeratinibBiological: NivolumabDrug: OlaparibDrug: OxaliplatinDrug: PalbociclibDrug: PanobinostatBiological: PembrolizumabBiological: PertuzumabDrug: PonatinibOther: Quality-of-Life AssessmentDrug: RegorafenibDrug: RuxolitinibDrug: SirolimusDrug: SorafenibDrug: SunitinibDrug: TrametinibBiological: Trastuzumab EmtansineDrug: TretinoinDrug: VemurafenibDrug: VenetoclaxDrug: VismodegibDrug: Vorinostat
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03878524
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 39
- Registration Number
- NCT03825289
- Locations
- 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Molecular Profiling of Advanced Soft-tissue Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-04-10
- Target Recruit Count
- 603
- Registration Number
- NCT03784014
- Locations
- 🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷IUCT Oncopôle, Toulouse, France
🇫🇷Institut de Cancérologie de Montpellier, Montpellier, France
Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Target Recruit Count
- 63
- Registration Number
- NCT03754179
- Locations
- 🇧🇪
UZ Brussel, Jette, Brabant, Belgium
Treatment of NF1-related Plexiform Neurofibroma With Trametinib
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Region Skane
- Target Recruit Count
- 15
- Registration Number
- NCT03741101
- Locations
- 🇸🇪
Skåne University Hospital, Lund, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.